Index

Α

```
ACCA, see adverse events
additives, 5
adjuvants, 4
administration of vaccines, 38
  simultaneous, 51
  timing of, 51
adverse events, 26, 59, 131
  Advisory Committee on Causality Assessment, 63
  and BCG, 154
  MMR and autism, 71,131, 233
  surveillance/reporting system, 62
  YFV-AND and YFV-AVD, 348
advocacy/opportunities for immunization, 24, 59, 96, 115
allergies
  as contraindication, 73, 74
  potential, 14
  to egg and related antigens, 85
aluminum, 4
anaphylaxis
  as contraindication, 73
  management in non-hospital setting, 80
autism, see MMR
avian influenza, 214
```

В

```
bat exposure and rabies, 286
Bacille-Calmette Guérin vaccine, 149
BCG and adverse events, 154
benefits of vaccines, 17, 24
bleeding disorders, 134
bovine reagents, 5
breakthrough varicella disease, see vaccine-modified disease, 327
breast-feeding and immunization, 107
```

C

```
Canadian Adverse Event Following Immunization Surveillance System, 62 cholera vaccine, 158 cold chain, 45 combination vaccines, 33 communicating effectively about immunization, 29 immunization truths, 31 resources, 32 risk communication, 29 congenital rubella syndrome, 298 congenital varicella syndrome, 328 consent and counselling, 29, 38 contraindications and precautions, 73 conditions not contraindications, 25, 75 cost of vaccines/other public health interventions, 20
```

D

diphtheria toxoid, 166

Ε

education
for parents, 24
providers, 27
egg allergy, see allergy
elderly patients, 115
expiry date of vaccines, 38, 47

G

gelatin, 5 Guillain-Barré syndrome, 74, 131, 218, 314

Н

Haemophilus vaccine, see Hib vaccine health care institutions immunization of patients, 115 health care providers and advocacy, 59, 96, 115 and hepatitis B, 193, 197 and influenza vaccine, 213, 215

```
occupational risk, immunization against, 102
hepatitis A vaccine, 179
  and universal immunization, 184
Hib vaccine, 172
Hib infection and immune deficiency, 175
HIV, 126, 127
human serum albumin, 5
Ig, see immune globulin
immigration
  immigration medical examination, 145
  immunization of persons new to Canada, 144
immune globulin, 53, 353
  interval between Ig and vaccine, 54
  specific immune globulins, 356
immune response, 117
immunization
  of adults, 96
  of patients in health care institutions, 115
  records, 55
  registries, 56
  risk groups for, 102
  routine for adults, 99
  schedules, 93
immunocompromised persons, 74, 117
immunosuppression, 73
inactivated vaccine, 4
incidence, see vaccine-preventable diseases
infants
  born prematurely, 113
  immunization schedule, 93
infection control in immunization, 42
influenza vaccine, 209
  avian influenza and culling operations, 214
  and Guillain-Barré syndrome, 218
  and health care workers, 213
  and oculorespiratory syndrome, 218
  recommended recipients, 215
injection route, 40
```

interchangeability of vaccines, 36 interval between Ig and vaccine, 54 intravenous Ig, 354

J

Japanese encephalitis vaccine,221

L

live attenuated vaccine, 4

M

measles vaccine, 228 MMR and autism, 131, 233 MMRV, 330 multiple injections, 41, 78 mumps vaccine, 251

N

National Guidelines for Immunization Practices, 22 neurological disorders, 131

0

occupational risk immunization against, 102

P

pain, techniques to decrease, 41
palivizumab, see RSV
passive immunization, 353
pertussis vaccine, 257
pneumococcal vaccine, 267
polio vaccine, 277
global eradication, 278
pregnancy, 73,107
and hepatitis B, 113, 115, 194
prematurity, see infants born prematurely preservative, 5
product monograph, 61

R

```
rabies vaccine, 285
records, immunization, 25, 55
inadequate, 105
regulatory authority, 59
risk communication, 29
RSV and palivizumab, 54, 114, 358
rubella vaccine, 298
congenital rubella syndrome, 298
genotyping, 306
IgG avidity testing, 305
```

S

```
safety of Ig, 355, 356
safety of vaccines, 59
  Advisory Committee on Causality Assessment, 63
  expert overviews, 69
  surveillance and assessment, 62
  vaccine evaluation and regulation, 59
schedules, immunization
  for adults, 96
  for infants and children, 93
self-injectors against anaphylaxis, 83
smallpox vaccine, 308
splenic disorders, 119
storage and handling, 45
subunit vaccine, 4
surveillance, see safety of vaccines
syringe selection, 39
```

T

```
tetanus toxoid, 309
thimerosal, 5
timing of vaccines, 51
travelers, recommended immunizations, 100, 136
tuberculin skin testing
as identification tool, 151
and measles vaccine, 76, 234
typhoid vaccine, 317
```

```
VAAESS, see Canadian Adverse Event Following Immunization Surveillance
System
vaccination
  opportunities for, 24
  errors, 28
  simultaneous, 51
vaccine-preventable diseases
  incidence of, 18, 31, inside back cover
vaccines
  administration, 38
  approval, 59
  attributable risk, 65
  benefits, 17, 24
  classification, 4
  combinations, 33
  currently approved, 7
  interchangeability, 36
  lyophilized, 46
  management, 27, 45
  multiple, 41, 71
  preparation, 38
  records, 25, 55
  safety, see safety of vaccines
  storage and handling, 45
  type, 4
vaccine-modified disease, 327
varicella vaccine, 327
  congenital varicella syndrome, 328
  and the immunocompromised, 331, 336
  recommended usage algorithms, 333, 334
  US data, 329
VarIg, 360
VariZIG, see VarIg, 360
yellow fever vaccine, 343
```

YFV-AND, 348 YFV-AVD, 348